Strategies for optimizing the response of cancer and normal tissues to radiation

Nature Reviews Drug Discovery

Volumn 12, Issue 7, 2013, Pages 526-542

  Moding, Everett J ^a   Kastan, Michael B ^a   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ACTIVATED PROTEIN C; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA CAROTENE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENTOLIMOD; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE; MELATONIN; MITOMYCIN; NAVITOCLAX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIMORAZOLE; PALIFERMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TEMOZOLOMIDE; TEMPOL; TIRAPAZAMINE; UNINDEXED DRUG; VANDETANIB;

ACUTE RADIATION SYNDROME; ALOPECIA; APOPTOSIS; BRACHYTHERAPY; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE CHECKPOINT; COLON CANCER; CYSTITIS; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; GENE MUTATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOMODULATION; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; IONIZING RADIATION; KIDNEY INJURY; LARYNX TUMOR; LUNG CANCER; LUNG FIBROSIS; LUNG INJURY; LUNG SMALL CELL CANCER; LYMPHOMA; MUCOSA INFLAMMATION; NERVOUS SYSTEM INJURY; NONHUMAN; PHARYNX TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION INJURY; RADIATION PROTECTION; RADIATION RESPONSE; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; TUMOR MICROENVIRONMENT; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; RADIATION DOSAGE; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84879636711     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4003     Document Type: Review

References (279)

1. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int. J. Radiat. Oncol. Biol. Phys. 51, 880-914 (2001).
2. Lo, S. S. et al. Stereotactic body radiation therapy: a novel treatment modality. Nature Rev. Clin. Oncol. 7, 44-54 (2010).
3. Timmerman, R. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 24, 4833-4839 (2006). (Pubitemid 46630909)
4. Forquer, J. A. et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother. Oncol. 93, 408-413 (2009).
5. Sahgal, A., Larson, D. A. & Chang, E. L. Stereotactic body radiosurgery for spinal metastases: a critical review. Int. J. Radiat. Oncol. Biol. Phys. 71, 652-665 (2008). (Pubitemid 351749532)
6. Andolino, D. L. et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 81, e447-e453 (2011).
7. Madsen, B. L. et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67, 1099-1105 (2007).
8. Svedman, C. et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 45, 870-875 (2006). (Pubitemid 44423134)
9. Timmerman, R. et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124, 1946-1955 (2003). (Pubitemid 37433596)
10. Durante, M. & Loeffler, J. S. Charged particles in radiation oncology. Nature Rev. Clin. Oncol. 7, 37-43 (2010).
11. Schulz-Ertner, D. & Tsujii, H. Particle radiation therapy using proton and heavier ion beams. J. Clin. Oncol. 25, 953-964 (2007). (Pubitemid 350002861)
12. Greco, C. & Wolden, S. Current status of radiotherapy with proton and light ion beams. Cancer 109, 1227-1238 (2007). (Pubitemid 46466548)
13. Sheets, N. C. et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307, 1611-1620 (2012).
14. Hoskin, P. J. & Bownes, P. Innovative technologies in radiation therapy: brachytherapy. Semin. Radiat. Oncol. 16, 209-217 (2006). (Pubitemid 44436961)
15. Bhide, S. A. & Nutting, C. M. Recent advances in radiotherapy. BMC Med. 8, 25 (2010).
16. Dawson, L. A. & Jaffray, D. A. Advances in image-guided radiation therapy. J. Clin. Oncol. 25, 938-946 (2007). (Pubitemid 350002859)
17. Elshaikh, M., Ljungman, M., Te n Haken, R. & Lichter, A. S. Advances in radiation oncology. Annu. Rev. Med. 57, 19-31 (2006). (Pubitemid 43261976)
18. Bernier, J., Hall, E. J. & Giaccia, A. Radiation oncology: a century of achievements. Nature Rev. Cancer 4, 737-747 (2004). (Pubitemid 39215072)
19. Seiwert, T. Y., Salama, J. K. & Vokes, E. E. The concurrent chemoradiation paradigm - general principles. Nature Clin. Practice. Oncol. 4, 86-100 (2007). (Pubitemid 46189538)
20. Nishimura, Y. Rationale for chemoradiotherapy. Int. J. Clin. Oncol. 9, 414-420 (2004).
21. Dewhirst, M. W., Cao, Y. & Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Rev. Cancer 8, 425-437 (2008). (Pubitemid 351744964)
22. Harrison, L. B., Chadha, M., Hill, R. J., Hu, K. & Shasha, D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492-508 (2002). (Pubitemid 36008998)
23. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L. & Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285-289 (1997). (Pubitemid 27318643)
24. Chapman, J. D. Hypoxic sensitizers - implications for radiation therapy. N. Engl. J. Med. 301, 1429-1432 (1979). (Pubitemid 10199238)
25. Overgaard, J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25, 4066-4074 (2007). (Pubitemid 47492951)
26. Bennett, M. H., Feldmeier, J., Smee, R. & Milross, C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst. Rev. 4, CD005007 (2012).
27. Henke, M. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260 (2003). (Pubitemid 37324251)
28. Arcasoy, M. O. et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin. Cancer Res. 11, 20-27 (2005). (Pubitemid 40075774)
29. Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46, 135-146 (1998). (Pubitemid 28109172)
30. Lee, D. J. et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32, 567-576 (1995).
31. Brown, J. M. & Koong, A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl Cancer Inst. 83, 178-185 (1991).
32. Rischin, D. et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28, 2989-2995 (2010).
33. Le, Q.-T. et al. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin. Cancer Res. 18, 1798-1807 (2012).
34. Sun, X., Niu, G., Chan, N., Shen, B. & Chen, X. Tumor hypoxia imaging. Mol. Imag. Biol. 13, 399-410 (2011).
35. Kouvaris, J. R., Kouloulias, V. E. & Vlahos, L. J. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12, 738-747 (2007). (Pubitemid 47036208)
36. Yuhas, J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-Aminopropylamino)- ethylphosphorothioic acid. Cancer Res. 40, 1519-1524 (1980). (Pubitemid 10101995)
37. Calabro-Jones, P. M., Fahey, R. C., Smoluk, G. D. & Ward, J. F. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 47, 23-27 (1985). (Pubitemid 15139195)
38. Yuhas, J. M. & Storer, J. B. Differential chemoprotection of normal and malignant tissues. J. Natl Cancer Inst. 42, 331-335 (1969).
39. Buentzel, J. et al. Intravenous amifostine during chemoradiotherapy for head-And-neck cancer: a randomized placebo-controlled Phase III study. Int. J. Radiat. Oncol. Biol. Phys. 64, 684-691 (2006). (Pubitemid 43183561)
40. Fournel, P. et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J. Clin. Oncol. 23, 5910-5917 (2005).
41. Lorusso, D. et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann. Oncol. 14, 1086-1093 (2003). (Pubitemid 36950173)
42. Hensley, M. L. et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27, 127-145 (2009).
43. Glover, D., Glick, J. H., Weiler, C., Fox, K. & Guerry, D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J. Clin. Oncol. 5, 574-578 (1987). (Pubitemid 17062494)
44. Rubin, J. S. et al. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J. Laryngol. Otol. 109, 744-747 (1995).
45. Mollman, J. E., Glover, D. J., Hogan, W. M. & Furman, R. E. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61, 2192-2195 (1988).
46. Murray-Zmijewski, F., Slee, E. A. & Lu, X. A complex barcode underlies the heterogeneous response of p53 to stress. Nature Rev. Mol. Cell Biol. 9, 702-712 (2008).
47. Schwachofer, J. H., Hoogenhout, J., Kal, H. B., Koedam, J. & van Wezel, H. P. Radiosensitivity of different human tumor lines grown as xenografts determined from growth delay and survival data. In Vivo 4, 253-257 (1990).
48. Gerweck, L. E., Zaidi, S. T. & Zietman, A. Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. Int. J. Radiat. Oncol. Biol. Phys. 29, 57-66 (1994). (Pubitemid 24138865)
49. Singh, M., Murriel, C. L. & Johnson, L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 72, 2695-2700 (2012).
50. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
51. Karar, J. & Maity, A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol. Ther. 8, 1994-2001 (2009).
52. Roses, R. E., Xu, M., Koski, G. K. & Czerniecki, B. J. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27, 200-207 (2008).
53. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Med. 13, 1050-1059 (2007). (Pubitemid 47517504)
54. + T cells: changing strategies for cancer treatment. Blood 11 4, 589-595 (2009).
55. Sharpless, N. E. & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev. Drug Discov. 5, 741-754 (2006). (Pubitemid 44323701)
56. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
57. Graves, E. E. et al. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin. Cancer Res. 16, 4843-4852 (2010).
58. Maity, A. & Koumenis, C. Location, location, location-makes all the difference for hypoxia in lung tumors. Clin. Cancer Res. 16, 4685-4687 (2010).
59. Singh, M. et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotech. 28, 585-593 (2010).
60. Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012).
61. Suit, H., Skates, S., Taghian, A., Okunieff, P. & Efird, J. T. Clinical implications of heterogeneity of tumor response to radiation therapy. Radiother. Oncol. 25, 251-260 (1992). (Pubitemid 23000767)
62. Brown, J. M. & Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391-1399 (1999). (Pubitemid 29160097)
63. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
64. Choudhury, A. et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 70, 7017-7026 (2010).
65. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
66. Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527-530 (2012).
67. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012).
68. + stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012).
69. Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007). (Pubitemid 46054518)
70. Baumann, M., Krause, M. & Hill, R. Exploring the role of cancer stem cells in radioresistance. Nature Rev. Cancer 8, 545-554 (2008). (Pubitemid 351881850)
71. Rich, J. N. Cancer stem cells in radiation resistance. Cancer Res. 67, 8980-8984 (2007). (Pubitemid 47535877)
72. Pajonk, F., Vlashi, E. & McBride, W. H. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28, 639-648 (2010).
73. Jang, Y.-Y. & Sharkis, S. J. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 11 0, 3056-3063 (2007). (Pubitemid 350006961)
74. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006). (Pubitemid 44949604)
75. Moncharmont, C. et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 322, 139-147 (2012).
76. Kaelin, W. G. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689-698 (2005).
77. Núñez, M. I., McMillan, T. J., Valenzuela, M. T., Ruiz de Almodóvar, J. M. & Pedraza, V. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Radiother. Oncol. 39, 155-165 (1996). (Pubitemid 26150455)
78. Jorgensen, T. J. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol. Ther. 8, 665-670 (2009).
79. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nature Rev. Cancer 8, 193-204 (2008). (Pubitemid 351301852)
80. Jagtap, P. & Szabó, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature Rev. Drug Discov. 4, 421-440 (2005). (Pubitemid 40704125)
81. Ratnam, K. & Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13, 1383-1388 (2007). (Pubitemid 46450426)
82. Tutt, A. & Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 8, 571-576 (2002). (Pubitemid 35408215)
83. De Soto, J. A et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int. J. Biol. Sci. 2, 179-185 (2006). (Pubitemid 44031562)
84. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
85. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
86. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006). (Pubitemid 44299177)
87. Löser, D. A. et al. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol. Cancer Ther. 9, 1775-1787 (2010).
88. Bryant, H. E. & Helleday, T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res. 34, 1685-1691 (2006).
89. Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 11 7, 1440-1449 (2007). (Pubitemid 46718432)
90. Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Rev. Drug Discov. 8, 627-644 (2009).
91. Rainey, M. D., Charlton, M. E., Stanton, R. V. & Kastan, M. B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 68, 7466-7474 (2008).
92. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004). (Pubitemid 39665530)
93. Westphal, C. H. et al. Loss of ATM radiosensitizes multiple p53 null tissues. Cancer Res. 58, 5637-5639 (1998). (Pubitemid 29006395)
94. Raso, A. et al. Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein. Brain Pathol. 22, 677-688 (2012).
95. Brown, E. J. & Baltimore, D. AT R disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397-402 (2000). (Pubitemid 30131885)
96. Brown, E. J. & Baltimore, D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17, 615-628 (2003). (Pubitemid 36307546)
97. Shechter, D., Costanzo, V. & Gautier, J. ATR and ATM regulate the timing of DNA replication origin firing. Nature Cell Biol. 6, 648-655 (2004). (Pubitemid 38960923)
98. Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-Associated mutations. Nature Struct. Mol. Biol. 18, 721-727 (2011).
99. Fokas, E. et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 3, e441 (2012).
100. Maira, S. M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
101. Konstantinidou, G. et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69, 7644-7652 (2009).
102. Mukherjee, B. et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-And DNA-PKCs-mediated DNA damage responses. Neoplasia 14, 34-43 (2012).
103. Gupta, A. K. et al. The Ras radiation resistance pathway. Cancer Res. 61, 4278-4282 (2001). (Pubitemid 32721000)
104. Fokas, E. et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 72, 239-248 (2012).
105. Dent, P., Yacoub, A., Fisher, P. B., Hagan, M. P. & Grant, S. MAPK pathways in radiation responses. Oncogene 22, 5885-5896 (2003). (Pubitemid 37176709)
106. Dent, P. et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat. Res. 159, 283-300 (2003). (Pubitemid 36314943)
107. Golding, S. E. et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 67, 1046-1053 (2007).
108. Kriegs, M. et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair 9, 889-897 (2010).
109. Andarawewa, K. L., Paupert, J., Pal, A. & Barcellos-Hoff, M. H. New rationales for using TGFbeta inhibitors in radiotherapy. Int. J. Radiat. Biol. 83, 803-811 (2007). (Pubitemid 350219100)
110. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550-562 (2009).
111. Gupta, A. K. et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8, 885-892 (2002). (Pubitemid 34742122)
112. Hambardzumyan, D. et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436-448 (2008). (Pubitemid 351272752)
113. Kim, I.-A. et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 65, 7902-7910 (2005). (Pubitemid 41297268)
114. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006). (Pubitemid 43209104)
115. Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010).
116. Eberhard, D. A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
117. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
118. Valerie, K. et al. Radiation-induced cell signaling: inside-out and outside-in. Mol. Cancer Ther. 6, 789-801 (2007). (Pubitemid 46554549)
119. Eriksson, D. & Stigbrand, T. Radiation-induced cell death mechanisms. Tumour Biol. 31, 363-372 (2010).
120. Letai, A. G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Rev. Cancer 8, 121-132 (2008). (Pubitemid 351161322)
121. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005). (Pubitemid 40825512)
122. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
123. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
124. Wilson, W. H. et al. Navitoclax, a targeted high-Affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149-1159 (2010).
125. Opferman, J. T. et al. Obligate role of anti-Apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101-1104 (2005). (Pubitemid 40262114)
126. Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671-676 (2003). (Pubitemid 38009376)
127. Skvara, H. et al. Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death. Anticancer Res. 25, 2697-2703 (2005).
128. Chen, S., Dai, Y., Harada, H., Dent, P. & Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67, 782-791 (2007). (Pubitemid 46192219)
129. Moretti, L., Li, B., Kim, K. W., Chen, H. & Lu, B. AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J. Thorac. Oncol. 5, 680-687 (2010).
130. Zerp, S. F. et al. AT-101, a small molecule inhibitor of anti-Apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat. Oncol. 4, 47 (2009).
131. Hudson, S. G. et al. Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells. Exp. Biol. Med. 238, 248-256 (2013).
132. Hollstein, M. Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutations in human cancers. Science 253, 49-53 (1991). (Pubitemid 21917115)
133. Wade, M., Wang, Y. V. & Wahl, G. M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20, 299-309 (2010).
134. Shangary, S. et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA 105, 3933-3938 (2008). (Pubitemid 351723502)
135. Vakifahmetoglu, H., Olsson, M. & Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 15, 1153-1162 (2008). (Pubitemid 351850968)
136. Xu, B., O'Donnell, A., Kim, S.-T. & Kastan, M. B. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res. 62, 4588-4591 (2002).
137. Xu, B., Kim, S.-T., Lim, D.-S. & Kastan, M. B. Tw o molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol. Cell. Biol. 22, 1049-1059 (2002). (Pubitemid 34094842)
138. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998). (Pubitemid 28538613)
139. Waldman, T. et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 3, 1034-1036 (1997). (Pubitemid 27391962)
140. Wouters, B. G., Giaccia, A. J., Denko, N. C. & Brown, J. M. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 57, 4703-4706 (1997). (Pubitemid 27468970)
141. Kirsch, D. G. et al. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 327, 593-596 (2010).
142. Komarova, E. A. et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23, 3265-3271 (2004). (Pubitemid 38669816)
143. Leibowitz, B. J. et al. Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. Mol. Cancer Res. 9, 616-625 (2011).
144. Lee, C. L. et al. p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice. Sci. Signal. 5, ra52 (2012).
145. Rowley, R., Hudson, J. & Young, P. G. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 356, 353-355 (1992).
146. Sarcar, B. et al. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol. Cancer Ther. 10, 2405-2414 (2011).
147. Wang, Y. et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 61, 8211-8217 (2001). (Pubitemid 33091614)
148. Caretti, V. et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol. Cancer Ther. 12, 141-150 (2013).
149. De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J. & Würdinger, T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 17, 4200-4207 (2011).
150. Bucher, N. & Britten, C. D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 98, 523-528 (2008). (Pubitemid 351214533)
151. Mitchell, J. B. et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin. Cancer Res. 16, 2076-2084 (2010).
152. Morgan, M. A. et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70, 4972-4981 (2010).
153. Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Rev. Cancer 7, 495-507 (2007). (Pubitemid 46985396)
154. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
155. Kozin, S. V., Duda, D. G., Munn, L. L. & Jain, R. K. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J. Natl Cancer Inst. 104, 899-905 (2012).
156. Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003). (Pubitemid 36583102)
157. Garcia-Barros, M. et al. Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res. 70, 8179-8186 (2010).
158. Truman, J. P. et al. Endothelial membrane remodeling is obligate for anti-Angiogenic radiosensitization during tumor radiosurgery. PLoS ONE 5, e12310 (2010).
159. Lin, X., Fuks, Z. & Kolesnick, R. Ceramide mediates radiation-induced death of endothelium. Crit. Care Med. 28, N87-N93 (2000). (Pubitemid 30262051)
160. Fuks, Z. & Kolesnick, R. Engaging the vascular component of the tumor response. Cancer Cell 8, 89-91 (2005). (Pubitemid 41132735)
161. Budach, W., Taghian, A., Freeman, J., Gioioso, D. & Suit, H. D. Impact of stromal sensitivity on radiation response of tumors. J. Natl Cancer Inst. 85, 988-993 (1993). (Pubitemid 23177585)
162. Gerweck, L. E., Vijayappa, S., Kurimasa, A., Ogawa, K. & Chen, D. J. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res. 66, 8352-8355 (2006). (Pubitemid 44449143)
163. Ogawa, K. et al. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res. 67, 4016-4021 (2007). (Pubitemid 46815045)
164. Ahn, G. O. & Brown, J. M. Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle 8, 970-976 (2009).
165. Ahn, G. O. & Brown, J. M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 12, 159-164 (2009).
166. Spring, H., Schuler, T., Arnold, B., Hammerling, G. J. & Ganss, R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl Acad. Sci. USA 102, 18111-18116 (2005). (Pubitemid 41798510)
167. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005). (Pubitemid 41317592)
168. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001). (Pubitemid 33063774)
169. Purhonen, S. et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105, 6620-6625 (2008). (Pubitemid 351754556)
170. Kozin, S. V., Duda, D. G., Munn, L. L. & Jain, R. K. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nature Rev. Cancer 11, 532 (2011).
171. Kozin, S. V. et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 70, 5679-5685 (2010).
172. Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705 (2010).
173. Ahn, G. O. & Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193-205 (2008). (Pubitemid 351318369)
174. Ahn, G. O. et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl Acad. Sci. USA 107, 8363-8368 (2010).
175. Tseng, D., Vasquez-Medrano, D. A. & Brown, J. M. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br. J. Cancer 104, 1805-1809 (2011).
176. Liu, S. K. et al. Delta-like ligand 4-Notch blockade and tumor radiation response. J. Natl Cancer Inst. 103, 1778-1798 (2011).
177. Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565-5570 (2000).
178. Dings, R. P. et al. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13, 3395-3402 (2007). (Pubitemid 46944928)
179. Teng, L.-S. et al. Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. JCMA 73, 281-288 (2010).
180. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145-147 (2004). (Pubitemid 38524883)
181. Willett, C. G. et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 27, 3020-3026 (2009).
182. Lai, A. et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29, 142-148 (2011).
183. Drappatz, J. et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78, 85-90 (2010).
184. Stiewe, T. The p53 family in differentiation and tumorigenesis. Nature Rev. Cancer 7, 165-168 (2007).
185. Gudkov, A. V. & Komarova, E. A. The role of p53 in determining sensitivity to radiotherapy. Nature Rev. Cancer 3, 117-129 (2003). (Pubitemid 37328879)
186. Komarova, E. A., Christov, K., Faerman, A. I. & Gudkov, A. V. Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 19, 3791-3798 (2000). (Pubitemid 30621185)
187. MacCallum, D. E. et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13, 2575-2587 (1996). (Pubitemid 27046113)
188. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993). (Pubitemid 23132161)
189. Yu, H. et al. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood 11 5, 3472-3480 (2010).
190. Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nature Rev. Cancer 9, 701-713 (2009).
191. Burdelya, L. G. et al. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res. 66, 9356-9361 (2006). (Pubitemid 44623629)
192. Gough, M. J. & Crittenden, M. R. Combination approaches to immunotherapy: the radiotherapy example. Immunotherapy 1, 1025-1037 (2009).
193. DuPage, M. et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19, 72-85 (2011).
194. DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405-409 (2012).
195. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-999 (2002).
196. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
197. Ehlers, G. & Fridman, M. Abscopal effect of radiation in papillary adenocarcinoma. Br. J. Radiol. 46, 220-222 (1973).
198. Kingsley, D. P. An interesting case of possible abscopal effect in malignant melanoma. Br. J. Radiol. 48, 863-866 (1975).
199. Nobler, M. P. The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation. Radiology 93, 410-412 (1969).
200. Ohba, K. et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43, 575-577 (1998). (Pubitemid 28462047)
201. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
202. Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862-870 (2004). (Pubitemid 38221143)
203. Hallahan, D. E., Spriggs, D. R., Beckett, M. A., Kufe, D. W. & Weichselbaum, R. R. Increased tumor necrosis factor α mRNA after cellular exposure to ionizing radiation. Proc. Natl Acad. Sci. USA 86, 10104-10107 (1989). (Pubitemid 20030785)
204. Hong, J. H. et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int. J. Radiat. Biol. 75, 1421-1427 (1999).
205. Nemoto, K. et al. Expression of IL-1β mRNA in mice after whole body X-irradiation. J. Radiat. Res. 36, 125-133 (1995).
206. Hareyama, M. et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer 67, 2269-2274 (1991).
207. Hauser, S. H., Calorini, L., Wazer, D. E. & Gattoni-Celli, S. Radiation-enhanced expression of major histocompatibility complex class I antigen H-2Db in B16 melanoma cells. Cancer Res. 53, 1952-1955 (1993). (Pubitemid 23127130)
208. Nesslinger, N. J. et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin. Cancer Res. 13, 1493-1502 (2007). (Pubitemid 46450440)
209. Schaue, D., Xie, M. W., Ratikan, J. A. & McBride, W. H. Regulatory T cells in radiotherapeutic responses. Front. Oncol. 2, 90 (2012).
210. Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728-734 (2005). (Pubitemid 40116901)
211. Kachikwu, E. L. et al. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81, 1128-1135 (2011).
212. Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion - from mechanism to translation. Nature Med. 17, 1391-1401 (2011).
213. Stone, H. B. et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat. Res. 162, 711-728 (2004). (Pubitemid 39552901)
214. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868 (1998). (Pubitemid 28124064)
215. Coppes, R. P., van der Goot, A. & Lombaert, I. M. Stem cell therapy to reduce radiation-induced normal tissue damage. Semin. Radiat. Oncol. 19, 112-121 (2009).
216. Blanpain, C, Mohrin, M., Sotiropoulou, P. A. & Passegue, E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8, 16-29 (2011).
217. Mitchell, J. B. et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys. 289, 62-70 (1991).
218. Metz, J. M. et al. A phase I study of topical tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin. Cancer Res. 10, 6411-6417 (2004). (Pubitemid 39346535)
219. Citrin, D. et al. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 15, 360-371 (2010).
220. Bairati, I. et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J. Clin. Oncol. 23, 5805-5813 (2005).
221. Meyer, F. et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int. J. Cancer 122, 1679-1683 (2008). (Pubitemid 351294980)
222. Robbins, M. E. & Zhao, W. Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int. J. Radiat. Biol. 80, 251-259 (2004). (Pubitemid 38736754)
223. Jack, C. I. et al. Indicators of free radical activity in patients developing radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 34, 149-154 (1996). (Pubitemid 26019964)
224. Kang, S. K. et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 57, 1056-1066 (2003). (Pubitemid 37324124)
225. Robbins, M. E., Zhao, W., Davis, C, Toyokuni, S. & Bonsib, S. M. Radiation-induced kidney injury: a role for chronic oxidative stress? Micron 33, 133-141 (2002). (Pubitemid 32997013)
226. Carpenter, M. et al. Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage. Gene Ther. 12, 685-693 (2005). (Pubitemid 40561507)
227. Lefaix, J. L. et al. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: an experimental study. Int. J. Radiat. Oncol. Biol. Phys. 35, 305-312 (1996).
228. Delanian, S. et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol. 32, 12-20 (1994). (Pubitemid 24246759)
229. Delanian, S., Balla-Mekias, S. & Lefaix, J. L. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J. Clin. Oncol. 17, 3283-3290 (1999). (Pubitemid 29470664)
230. Lefaix, J. L. et al. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and a-tocopherol: an experimental study. Int. J. Radiat. Oncol. Biol. Phys. 43, 839-847 (1999).
231. Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy Science 285, 1733-1737 (1999). (Pubitemid 29428873)
232. Takagi, M., Absalon, M. J., McLure, K. G. & Kastan, M. B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123, 49-63 (2005). (Pubitemid 41414528)
233. Chen, J. & Kastan, M. B. 5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev. 24, 2146-2156 (2010).
234. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006). (Pubitemid 44387609)
235. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012).
236. Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571-583 (2011).
237. Okatani, Y., Wakatsuki, A., Shinohara, K., Kaneda, C. & Fukaya, T. Melatonin stimulates glutathione peroxidase activity in human chorion. J. Pineal Res. 30, 199-205 (2001). (Pubitemid 32336902)
238. Akagi, T. et al. Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect. J. Pharmacol. Exp. Ther. 308, 378-384 (2004). (Pubitemid 38090740)
239. Berk, L. et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int. J. Radiat. Oncol. Biol. Phys. 68, 852-857 (2007). (Pubitemid 46818740)
240. Bertho, J.-M. et al. Comparison of autologous cell therapy and granulocyte-colony stimulating factor (G-CSF) injection versus G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model. Int. J. Radiat. Oncol. Biol. Phys. 63, 911-920 (2005). (Pubitemid 41400083)
241. Uckun, F. M., Souza, L., Waddick, K. G., Wick, M. & Song, C. W. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood 75, 638-645 (1990). (Pubitemid 20069203)
242. Finch, P. W. & Rubin, J. S. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv. Cancer Res. 91, 69-136 (2004). (Pubitemid 39140957)
243. Lombaert, I. M. et al. Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of the stem/progenitor pool. Stem Cells 26, 2595-2601 (2008).
244. Farrell, C. L. et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int. J. Radiat. Biol. 75, 609-620 (1999). (Pubitemid 29243139)
245. Brizel, D. M. et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J. Clin. Oncol. 26, 2489-2496 (2008).
246. Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001). (Pubitemid 32694744)
247. Schuller, B. W. et al. No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome. Int. J. Radiat. Oncol. Biol. Phys. 68, 205-210 (2007). (Pubitemid 46589862)
248. Fuks, Z. et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 54, 2582-2590 (1994). (Pubitemid 24173742)
249. Rotolo, J. et al. Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice. J. Clin. Invest. 122, 1786-1790 (2012).
250. Zhang, L. et al. Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 77, 261-268 (2010).
251. Wang, Y. et al. Activation of nuclear factor κB in vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res. 64, 6240-6246 (2004). (Pubitemid 39129426)
252. Burdelya, L. G. et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226-230 (2008). (Pubitemid 351521417)
253. Martin, M., Lefaix, J. & Delanian, S. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47, 277-290 (2000). (Pubitemid 30236366)
254. Anscher, M. S., Thrasher, B., Rabbani, Z., Teicher, B. & Vujaskovic, Z. Antitransforming growth factor-β antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 65, 876-881 (2006). (Pubitemid 43795819)
255. Anscher, M. S. et al. Small molecular inhibitor of transforming growth factor-β protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 71, 829-837 (2008).
256. Zheng, H., Wang, J., Koteliansky, V. E., Gotwals, P. J. & Hauer-Jensen, M. Recombinant soluble transforming growth factor β type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 1 1 9, 1286-1296 (2000).
257. Verheij, M., Stewart, F., Oussoren, Y., Weening, J. & Dewit, L. Amelioration of radiation nephropathy by acetylsalicylic acid. Int. J. Radiat. Biol. 67, 587-596 (1995).
258. Wang, J. et al. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. J. Thromb. Haemost. 2, 2027-2035 (2004). (Pubitemid 40192757)
259. Wang, J. et al. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine. Thromb. Haemostasis 87, 122-128 (2002). (Pubitemid 34092586)
260. Glantz, M. J. et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44, 2020-2027 (1994). (Pubitemid 24349499)
261. Mosnier, L. O., Zlokovic, B. V. & Griffin, J. H. The cytoprotective protein C pathway. Blood 109, 3161-3172 (2007). (Pubitemid 46572500)
262. Geiger, H. et al. Pharmacological targeting of the thrombomodulin- Activated protein C pathway mitigates radiation toxicity. Nature Med. 18, 1123-1129 (2012).
263. Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Rev. Drug Discov. 4, 977-987 (2005).
264. Williams, J. P. et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat. Res. 161, 560-567 (2004). (Pubitemid 40754225)
265. Wang, J. et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 68, 1483-1490 (2007). (Pubitemid 47176821)
266. Haydont, V. et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int. J. Radiat. Oncol. Biol. Phys. 68, 1471-1482 (2007). (Pubitemid 47176803)
267. Daynes, R. A. & Jones, D. C. Emerging roles of PPARs in inflammation and immunity. Nature Rev. Immunol. 2, 748-759 (2002). (Pubitemid 37328715)
268. Ramanan, S. et al. The PPARα agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 75, 870-877 (2009).
269. Molteni, A. et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-β (TGF-β) and α-Actomyosin (α SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Design 13, 1307-1316 (2007). (Pubitemid 46746368)
270. Moulder, J. E., Fish, B. L. & Cohen, E. P. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr. Pharm. Design 9, 737-749 (2003). (Pubitemid 36367595)
271. Ryu, S., Kolozsvary, A., Jenrow, K. A., Brown, S. L. & Kim, J. H. Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time. J. Neuro-Oncol. 82, 119-124 (2007). (Pubitemid 46431853)
272. Moulder, J. E. & Cohen, E. P. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin. Radiat. Oncol. 17, 141-148 (2007). (Pubitemid 46467384)
273. Waselenko, J. K. et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann. Internal Med. 140, 1037-1051 (2004).
274. Lombaert, I. M. et al. Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS ONE 3, e2063 (2008).
275. Vieyra, D. S., Jackson, K. A. & Goodell, M. A. Plasticity and tissue regenerative potential of bone marrow-derived cells. Stem Cell Rev. 1, 65-69 (2005). (Pubitemid 41003466)
276. Lombaert, I. M. et al. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin. Cancer Res. 12, 1804-1812 (2006).
277. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999). (Pubitemid 29282067)
278. Epperly, M. W. et al. Bone marrow origin of cells with capacity for homing and differentiation to esophageal squamous epithelium. Radiat. Res. 162, 233-240 (2004). (Pubitemid 39295423)
279. Murry, C. E. & Keller, G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661-680 (2008). (Pubitemid 351260059)